In a patient with dementia and sundowning who is currently receiving quetiapine (Seroquel) 25 mg twice daily and is agitated and restless at night, what additional pharmacologic options are appropriate?

Additional Pharmacologic Options for Nighttime Agitation in Dementia with Sundowning

Add trazodone 25-50 mg at bedtime as the first-line agent for nighttime agitation and restlessness in this patient already on quetiapine. 1

Rationale and Treatment Algorithm

Your patient is on a relatively low dose of quetiapine (25 mg BID = 50 mg total daily), which is below the typical effective range for agitation control in dementia (initial dosing starts at 12.5 mg BID with maximum up to 200 mg BID) 1. However, before simply escalating the quetiapine, consider adding a targeted agent for the specific nighttime symptoms.

First-Line Addition: Trazodone

Trazodone is specifically recommended as a mood-stabilizing/antiagitation drug for dementia patients 1:

• Starting dose: 25 mg at bedtime
• Titration: Increase by 25-50 mg increments every 5-7 days as needed
• Maximum dose: 200-400 mg/day in divided doses
• Key advantage: More sedating properties that specifically target nighttime restlessness and insomnia
• Caution: Use with caution if the patient has premature ventricular contractions

Trazodone has shown benefit in controlled trials for agitation in dementia and is particularly useful for patients with agitated depression and insomnia 1. Recent palliative care guidelines also support trazodone 25-100 mg at bedtime for refractory insomnia 2.

Alternative or Additional Options if Trazodone Insufficient

If trazodone alone doesn't adequately control symptoms after 2-4 weeks at therapeutic doses:

Option 1: Optimize the Quetiapine

• The current dose (25 mg BID) can be increased incrementally
• Per FDA labeling, elderly patients should start at 50 mg/day with increases of 50 mg/day 3
• Target range for agitation: typically 100-200 mg/day total
• Important caveat: Recent 2025 data shows low-dose quetiapine for insomnia in older adults is associated with increased mortality (HR 3.1), dementia progression (HR 8.1), and falls (HR 2.8) compared to trazodone 4. This strongly supports using trazodone first rather than escalating quetiapine.

Option 2: Mirtazapine

• Dose: 7.5-30 mg at bedtime 1
• Advantages: Potent, well-tolerated, promotes sleep, appetite, and weight gain
• Particularly effective in patients with depression and anorexia 2
• May be safer than quetiapine based on recent comparative data 4

Option 3: Divalproex Sodium (Depakote)

• Starting dose: 125 mg twice daily 1
• Titration: Titrate to therapeutic blood level (40-90 mcg/mL)
• Advantage: Generally better tolerated than other mood stabilizers for agitation
• Monitoring: Liver enzymes, platelets, PT/PTT as indicated
• Useful alternative to antipsychotics for severe agitated, repetitive, and combative behaviors

What NOT to Do

Avoid benzodiazepines (lorazepam, temazepam, etc.) 1:

• Regular use leads to tolerance, addiction, depression, and cognitive impairment
• Paradoxical agitation occurs in ~10% of dementia patients
• Should be avoided in older patients and those with cognitive impairment 2

Do not use typical antipsychotics (haloperidol, etc.) as first-line 1:

• Associated with significant side effects (cholinergic, cardiovascular, extrapyramidal)
• 50% risk of irreversible tardive dyskinesia after 2 years of continuous use in elderly
• Reserve as second-line only if atypical antipsychotics fail

Non-Pharmacologic Interventions to Implement Concurrently

Before or alongside medication adjustments:

• Environmental modifications: Structured activities during the day, minimize daytime napping, increase light exposure during daytime hours
• Sleep hygiene: Consistent bedtime routine, reduce evening stimulation
• Rule out reversible causes: Pain, urinary retention, constipation, infection, medication side effects
• Consider if cholinesterase inhibitor indicated: If not already on one, donepezil may help with sundowning symptoms 5

Monitoring and Reassessment

• Reassess after 4 weeks at therapeutic dose of any added agent 6
• If no clinically significant response after 4 weeks at adequate dose, taper and discontinue that medication 6
• Use a quantitative measure (e.g., Neuropsychiatric Inventory) to track response 6
• After 9 months of stability, attempt dose reduction to reassess need for continued treatment 1

Critical Safety Considerations

Black Box Warning Context: While quetiapine and other antipsychotics carry increased mortality risk in elderly dementia patients, the 2016 APA guidelines acknowledge their use when symptoms are severe, dangerous, or cause significant distress, after thorough risk-benefit discussion 6. The key is using the lowest effective dose and regular reassessment.

Bottom line: Start trazodone 25 mg at bedtime, titrate up to 50-100 mg as needed over 1-2 weeks, and reassess. This approach is safer than escalating quetiapine based on recent comparative safety data 4 and is specifically recommended for nighttime agitation in dementia 1.